AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20577706
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine patches (LP)
Trial: 17498072
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with rFVIIa and APCC
Trial: 11756906
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution injection (1‐2 mL boluses; mean volume 30 mL)
Trial: 11756906
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution injection
Trial: 7979927
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (progressive interval training with bicycle exercises, heel lifts, and step-climbing, performed twice weekly for 45 minutes over 3 months)
Trial: 28927673
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 to 60 mg/day for 14 days)
Trial: 22045924
Drug: DPP4 inhibitor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor, sitagliptin
Trial: 20191713
Drug: Comparison treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison treatments
Trial: 9449907
Drug: 0.5% podofilox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podofilox gel
Trial: 7637723
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg per day)
Trial: 2699466
Drug: Doxofylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline (400 mg twice daily)
Trial: 2699466
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline (300 mg twice daily)
Trial: 31236888
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g of oral DKP daily (Group A)
Trial: 31236888
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Diane‐35 orally daily (Group B)
Trial: 31236888
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g of oral DKP daily plus 1 tablet of Diane‐35 orally daily (Group C)
Trial: 23378417
Drug: Cholecalciferol (25,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (25,000 IU) therapy every 2 weeks
Trial: 20188537
Drug: Dynamic Conformal
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic Conformal Arc Therapy (DCAT)
Trial: 17595892
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg i.v. (administered over 30 min)
Trial: 17595892
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg i.v. (administered over 30 min)
Trial: 17595892
Drug: Esomeprazole 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Trial: 17595892
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Trial: 15077462
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with loperamide 2‐6 mg/day for 2 months
Trial: 9707184
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy before randomization (tPA 9%, placebo 9%)
Trial: 9707184
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy after randomization (tPA 24%, placebo 29%)
Trial: 9707184
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy after randomization for tPA patients
Trial: 21159021
Drug: 1 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg·kg(‐1) of clonidine
Trial: 21159021
Drug: 2 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg·kg(‐1) of clonidine
Trial: 21159021
Drug: 3 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 μg·kg(‐1) of clonidine
Trial: 15086603
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy (EIS) (13 patients; group B)
Trial: 11232676
Drug: 1-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Trial: 11232676
Drug: 2-week treatment
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Trial: 8607560
Drug: FPANS 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPANS 200 micrograms twice daily (bd)
Trial: 8607560
Drug: FPANS 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPANS 200 micrograms once daily (od)
Trial: 1071608
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment with metolazone or hydrochlorothiazide
Trial: 1071608
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (before treatment)
Trial: 30474376
Drug: Multilevel church-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel church-based intervention including sermons, educational handouts, vegetable and fruit gardens, cooking and nutrition classes, daily mobile messaging, community mapping, and policy changes over 5 months.
Trial: 24897394
Drug: Oxytocin administered
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered after placenta separation (Group 1)
Trial: 24897394
Drug: Oxytocin administered
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered after delivery of the shoulder (Group 2)
Trial: 19575235
Drug: Toltrazuril (Baycox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toltrazuril (Baycox 5% suspension)
Trial: 18396608
Drug: Pre-packaging antimalarial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-packaging antimalarial drugs and counselling
Trial: 11798728
Drug: H(2) strain
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H(2) strain vaccine
Trial: 7950211
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) and Traditional Chinese Medicine (TCM)
Trial: 7950211
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with same western medicine but no TCM
Trial: 2906458
Drug: Roxatidine acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate, 75 mg twice daily
Trial: 2906458
Drug: Roxatidine acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate, 150 mg at bedtime
Trial: 2906458
Drug: Roxatidine acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate, 150 mg after evening meal
Trial: 25837277
Drug: Sertraline vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline vs Placebo
Trial: 23295630
Drug: Short-term supportive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term supportive psychodynamic therapy (PDT)
Trial: 23295630
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PDT + Antidepressants)
Trial: 19221060
Drug: 3D ultrasonography
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D ultrasonography (US) enhanced with a perflubutane microbubble contrast agent
Trial: 16536197
Drug: Prompt L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L‐Pop (3M ESPE)
Trial: 10690389
Drug: Melphalan 8
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 8 mg/m2/d x 4 weeks x 18 courses
Trial: 8438599
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) and Molsidomine (ML)
Trial: 3887254
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of trimethoprim
Trial: 3887254
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of co-trimoxazole
Trial: 26725450
Drug: High-dose vaccine
RxNorm normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vaccine (5×10^10 viral particles)
Trial: 26725450
Drug: Low-dose vaccine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaccine (2.5×10^10 viral particles)
Trial: 24431901
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of autologous bone marrow-derived mesenchymal stem cells (MSCs)
Trial: 18251758
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 0.1 mg imidafenacin
Trial: 18251758
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.028 mg imidafenacin
Trial: 16855626
Drug: Two classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two classes of antihypertensive medication
Trial: 16855626
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more classes of antihypertensive medication
Trial: 16855626
Drug: Doctor diagnosis
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor diagnosis of hypertension and taking antihypertensive medication
Trial: 9082840
Drug: Innogem (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innogem (300 mg)
Trial: 9082840
Drug: Lopid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopid (300 mg)
Trial: 1900977
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue‐type plasminogen activator (100 mg over 3 hours, group A)
Trial: 1900977
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment (group B)
Trial: 7011469
Drug: sulpiride (600-1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulpiride (600-1,800 mg/day)
Trial: 7011469
Drug: trifluoperazine (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trifluoperazine (15-45 mg/day)
Trial: 25869815
Drug: Naftopidil (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (75 mg once in the morning and placebo twice a day)
Trial: 25869815
Drug: Flopropione (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flopropione (80 mg three times a day)
Trial: 24005170
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no salvage therapies)
Trial: 20601033
Drug: Initial systemic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial systemic treatment for cGVHD
Trial: 11333843
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg x kg(‐1) x d(‐1) lysine intake
Trial: 11333843
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg x kg(‐1) x d(‐1) lysine intake
Trial: 11333843
Drug: 28 mg
RxNorm normalized name: aspirin 228 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 mg x kg(‐1) x d(‐1) lysine intake
Trial: 11333843
Drug: 36 mg
RxNorm normalized name: pyrantel 136 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg x kg(‐1) x d(‐1) lysine intake
Trial: 3113290
Drug: Epidural morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine, 4 mg
Trial: 3113290
Drug: Epidural buprenorphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine, 0.15 mg
Trial: 3113290
Drug: Epidural buprenorphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine, 0.3 mg
Trial: 27318048
Drug: High ligation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ligation and stripping with and without patch saphenoplasty
Trial: 26040543
Drug: Rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation group (RG) - complex multi-method rehabilitation intervention including structured education, cognitive behavioral therapy (CBT), progressive individualized exercise, and peer support.
Trial: 16189255
Drug: Depot estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot estradiol, 0.2 mg/month i.m. with GH 0.05 mg/kg daily
Trial: 10658893
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT, n = 30)
Trial: 8841871
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of allopurinol 18 hours and 400 mg of allopurinol orally 3 hours before surgery
Trial: 1632701
Drug: Intradermal OK-432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal OK-432
Trial: 1632701
Drug: Oral OK-432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OK-432 with preserved spleen
Trial: 6499513
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pivmecillinam twice-daily for 3 days
Trial: 6499513
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pivmecillinam twice-daily for 7 days
Trial: 21340661
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days
Trial: 21340661
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin qd for 11 days
Trial: 12544367
Drug: Notoginseny cream
RxNorm normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Notoginseny cream
Trial: 12544367
Drug: Hirudoid cream
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudoid cream (Control)
Trial: 10787394
Drug: Acamprosate 666
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 666 mg three times/day
Trial: 1626496
Drug: Colestipol 5
RxNorm normalized name: colestipol 5 g oral granule for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 5 g/day
Trial: 1626496
Drug: Colestipol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 10 g/day
Trial: 1626496
Drug: Colestipol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 15 g/day
Trial: 27852965
Drug: D-cycloserine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (100 mg, 200 mg, and 400 mg for two weeks each)
Trial: 24937016
Drug: Enhanced intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced intervention (monthly counseling phone calls, weekly mailings with tailored and non-tailored materials, videos)
Trial: 22100204
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of misoprostol sublingually
Trial: 12374540
Drug: rhIL-10 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-10 (20 micro g/kg) subcutaneously 3 times weekly for 12 weeks
Trial: 12374540
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously 3 times weekly for 12 weeks
Trial: 2106162
Drug: Ifosfamide 2
RxNorm normalized name: ifosfamide 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection
Trial: 2106162
Drug: Doxorubicin, ifosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin, ifosfamide, dacarbazine at doses of 60, 7,500, and 900 mg/m2 respectively by continuous infusion over 72 hours
Trial: 2106162
Drug: Observation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation in the adjuvant treatment of high-grade sarcomas
Trial: 6154838
Drug: Clonidine +
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine + Diuretic
Trial: 6154838
Drug: Clonidine +
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine + Diuretic + Vasodilator
Trial: 31162860
Drug: Humidified oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified oxygen therapy
Trial: 31162860
Drug: Non-humidified oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-humidified oxygen therapy
Trial: 7605521
Drug: Penicillinase-resistant antibiotics
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillinase-resistant antibiotics
Trial: 2257957
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day ranitidine plus placebo (group I)
Trial: 2257957
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II)
Trial: 2257957
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III)
Trial: 2257957
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (analgesic activity)
Trial: 29674981
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care with pain medication
Trial: 29674981
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication (paracetamol, COX inhibitors, pregabalin)
Trial: 28233311
Drug: UVA-1 phototherapy
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA-1 phototherapy at 30 J/cm2, escalated to 60 J/cm2 if hair regrowth was <75%, and further escalated to 120 J/cm2 if necessary; total of 25 sessions administered.
Trial: 24547881
Drug: Isotretinoin 30
RxNorm normalized name: isotretinoin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 30 mg/day
Trial: 21415430
Drug: Remifentanil-propofol combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil-propofol combinations (remifentanil 0.8 to 1.6 ng · mL(‐1) and propofol 1.5 to 2.7 μg · mL(‐1))
Trial: 21415430
Drug: Remifentanil-propofol combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil-propofol combinations (remifentanil approximately 3.0 to 4.0 ng · mL(‐1) and propofol 0.0 to 1.1 μg · mL(‐1))
Trial: 18362863
Drug: Sexual risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, younger age at sexual debut)
Trial: 18362863
Drug: Sexual risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, enrolling both sex and drug network members)
Trial: 16608139
Drug: Liquid nutrition
RxNorm normalized name: Liquid Nutrition Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutrition supplement (200 ml) once daily immediately after diagnosis of infection
Trial: 16608139
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (enriched food after referral to a dietician)
Trial: 10450257
Drug: Nortriptyline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline at 80-120 ng/ml
Trial: 10450257
Drug: Nortriptyline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline at 40-60 ng/ml
Trial: 7558388
Drug: Medical Grade
RxNorm normalized name: Skarcade Medical Grade Silicone Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Grade Silicone Rubber (MSR) with an oval 15 mm clamp, volume of 0.1531 +/- 0.0059 ml injected by five to six turns of the applicator handwheel.
Trial: 486628
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (n = 22)
Trial: 26670076
Drug: Unilateral dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral dose adjusted ovarian drilling (ULOD) using 60 Joules/cm(3) applied to the larger ovary
Trial: 26670076
Drug: Bilateral ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ovarian drilling (BLOD) with fixed doses of 1200 J
Trial: 25141218
Drug: Laser+EX (diode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser+EX (diode laser 980 nm, 20 W, fluence 37.5 J/cm², total energy 1200 J, thrice weekly for 3 weeks)